CytRx to Present at Upcoming Investor Conferences

Rhea-AI Summary

CytRx Corporation (OTCQB: CYTR) announced that CEO Steven A. Kriegsman will present at two upcoming virtual conferences:

• LD Micro Invitational XI Conference: June 9, 2021, at 10:30 a.m. PT.
• Global Chinese Financial Forum: June 10, 2021, at 8:10 a.m. PT.

Mr. Kriegsman aims to discuss CytRx’s licensing agreements and developments with partners including Orphazyme A/S and ImmunityBio. Notably, Orphazyme is preparing for regulatory approvals for arimoclomol in Niemann-Pick disease Type C treatment, while ImmunityBio expands trials for aldoxorubicin in pancreatic cancer.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to present in the following upcoming conferences:

• LD Micro Invitational XI Conference: June 8-10, 2021
  • Mr. Kriegsman will deliver a virtual presentation on Wednesday, June 9, 2021, at 10:30 a.m. PT. The event will be webcast live and available for registrants via the event homepage.
  • As a reminder, CytRx joined the LD Micro Index in 2021.
• Global Chinese Financial Forum (“GCFF”) Virtual Conference 2021 – Healthcare Investment Conference: June 10, 2021
  • Mr. Kriegsman will deliver a virtual presentation on Thursday, June 10, 2021, at 8:10 am PT. The event will be webcast live for registrants via the event page.

Mr. Kriegsman commented:

“CytRx is excited to be participating in the upcoming LD Micro Invitational XI Conference and the GCFF Conference, where we will be discussing our portfolio of high-potential licensing agreements and strategic assets. In particular, we are looking forward to connecting with Chinese investors to share CytRx’s developments surrounding our agreements with Orphazyme A/S and ImmunityBio, Inc., as well as Centurion Biopharma. We are pleased that Orphazyme is preparing for prospective regulatory approvals for arimoclomol in the treatment of Niemann-Pick disease Type C and ImmunityBio is expanding its scope of clinical trials involving aldoxorubicin to treat advanced pancreatic cancer.”

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.

About LD Micro

LD Micro was founded in 2006 as an independent resource to the microcap world and quickly grew to the premier event platform in the space, LDmicro.com. In September of 2020, LD Micro was acquired by SRAX, who recently hosted the LD Micro event on their Sequire platform, ve.mysequire.com.

About GCFF Healthcare Investment Conference

The GCFF Healthcare investment conference (virtual) will be held on June 10, 2021. The aim for this event is to connect Chinese investors across the West and East coast (Vancouver, Los Angeles, San Francisco, Calgary, Toronto, New York City) and introduce them to some exciting opportunities in the healthcare sector (biotech, medical device, medtech, etc.). The sponsor expects to have 400-500 Chinese investors and investment advisors to be online at any given time during the event. Investors like to learn about the latest market trends and new investment opportunities in the stock market. The Chinese investor community is quite underserved and one market segment that public companies in North America should not ignore.

The GCFF Conference has been established for over 20 years and is one of its kind in serving the high net-worth Chinese investor market. They are the leading market intelligence firm that introduces investment opportunities in life science, resource and technology sectors to the Chinese investors in North America and Asia. They also run a high-traffic investment portal NAI500 and newsletter (over 72,000 opt-in subscribers) to serve the growing Chinese investor population.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005271/en/

FAQ

When is CytRx's presentation at the LD Micro Invitational XI Conference?

CytRx's presentation at the LD Micro Invitational XI Conference is scheduled for June 9, 2021, at 10:30 a.m. PT.

What will Steven A. Kriegsman discuss at the GCFF Virtual Conference?

At the GCFF Virtual Conference on June 10, 2021, Steven A. Kriegsman will discuss CytRx’s licensing agreements and partnerships with Orphazyme and ImmunityBio.

What is CytRx's focus in the biopharmaceutical sector?

CytRx focuses on research and development for oncology and neurodegenerative diseases.

How is Orphazyme involved with CytRx?

Orphazyme is developing CytRx's drug candidate, arimoclomol, for Niemann-Pick disease Type C and Gaucher disease.

What is the significance of aldoxorubicin for CytRx?

Aldoxorubicin is an advanced drug conjugate developed by CytRx, now licensed to ImmunityBio for treating advanced pancreatic cancer.